ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 12.48% |
2KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 5.36% |
3SYRE | SPYRE THERAPEUTICS INC | Healthcare | $9.77B | 4.83% |
4PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $9.08B | 4.49% |
5KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 4.48% |
6PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 4.33% |
7ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 3.52% |
8CGON | CG ONCOLOGY INC | Healthcare | $6.27B | 3.10% |
9MANE | VERADERMICS INC | Healthcare | $5.71B | 2.82% |
10GRAL | GRAIL INC | Healthcare | $5.46B | 2.70% |
11DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 2.57% |
12EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 2.48% |
13DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.52B | 2.23% |
14TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 2.08% |
15XENE | XENON PHARMACEUTICALS INC | Healthcare | $4.03B | 1.99% |
16RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 1.97% |
17PLSE | PULSE BIOSCIENCES INC | Healthcare | $3.84B | 1.90% |
18AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $3.84B | 1.90% |
19ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.56B | 1.76% |
20PBLS | PARABILIS MEDICINES INC | Healthcare | $3.42B | 1.69% |
21AXGN | AXOGEN INC | Healthcare | $3.31B | 1.64% |
22IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 1.50% |
23MBX | MBX BIOSCIENCES INC | Healthcare | $2.71B | 1.34% |
24CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.24B | 1.11% |
25IMNM | IMMUNOME INC | Healthcare | $2.21B | 1.09% |
26TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Healthcare | $2.05B | 1.01% |
27VCYT | VERACYTE INC | Healthcare | $1.99B | 0.98% |
28TRVI | TREVI THERAPEUTICS INC | Healthcare | $1.94B | 0.96% |
29AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $1.90B | 0.94% |
30BRVE | BRAVEHEART BIO INC | Healthcare | $1.84B | 0.91% |
31COAG | HEMAB THERAPEUTICS HOLDINGS INC | Healthcare | $1.84B | 0.91% |
32KLRA | KAILERA THERAPEUTICS INC | Healthcare | $1.72B | 0.85% |
33SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.80% |
34ABSI | ABSCI CORP | Healthcare | $1.57B | 0.77% |
35RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.76% |
36GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.70% |
37LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.68% |
38TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.67% |
39DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.67% |
40AVLN | AVALYN PHARMA INC | Healthcare | $1.36B | 0.67% |
41ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.61% |
42SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 0.55% |
43IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.54% |
44SPTX | SEAPORT THERAPEUTICS INC | Healthcare | $1.08B | 0.53% |
45JBIO | JADE BIOSCIENCES INC | Healthcare | $1.01B | 0.50% |
46BBNX | BETA BIONICS INC | Healthcare | $898M | 0.44% |
47CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $896M | 0.44% |
48ORIC | ORIC PHARMACEUTICALS INC | Healthcare | $881M | 0.44% |
49LTGO | LATIGO BIOTHERAPEUTICS INC | Healthcare | $857M | 0.42% |
50SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 0.39% |
51DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.37% |
52AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 0.37% |
53ATTO | ATTOVIA THERAPEUTICS INC | Healthcare | $723M | 0.36% |
54JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.35% |
55NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.34% |
56FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.34% |
57QUIT | ACHIEVE LIFE SCIENCES INC | Healthcare | $692M | 0.34% |
58SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.34% |
59DSGN | DESIGN THERAPEUTICS INC | Healthcare | $678M | 0.33% |
60AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $676M | 0.33% |
61BCAX | BICARA THERAPEUTICS INC | Healthcare | $671M | 0.33% |
62CLYM | CLIMB BIO INC | Healthcare | $639M | 0.32% |
63IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.29% |
64CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.26% |
65NGNE | NEUROGENE INC | Healthcare | $495M | 0.24% |
66MNPR | MONOPAR THERAPEUTICS | Healthcare | $488M | 0.24% |
67AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.22% |
68PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.21% |
69TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.21% |
70ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $411M | 0.20% |
71CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $384M | 0.19% |
72MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.16% |
73BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.16% |
74EVMN | EVOMMUNE INC | Healthcare | $291M | 0.14% |
75VOGX | VOGENX INC | Healthcare | $285M | 0.14% |
76FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.14% |
77QTTB | Q32 BIO INC | Healthcare | $264M | 0.13% |
78BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.13% |
79UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.12% |
80KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.10% |
81RLYB | RALLYBIO CORP | Healthcare | $84M | 0.04% |
82VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.04% |
83YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.03% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $202.39B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 73% toward Large, 48% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 83 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 83 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.10 (fail) but Gaussian VaR gives 1.92 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 4.5% | -16.6% |
| 3 yearsp.a. | 25.4% | 4.9% |
| 5 yearsp.a. | 0.8% | -13.4% |
| 10 yearsp.a. | 6.4% | -8.4% |
| Since inceptionp.a. | 3.3% | -6.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 6.5% | -15.4% |
| 2025 | 22.7% | -1.5% |
| 2024 | 21.7% | 14.4% |
| 2023 | -2.7% | -8.0% |
| 2022 | -26.5% | -31.2% |
| 2021 | -40.6% | -54.6% |
| 2020 | 55.2% | 33.0% |
| 2019 | 23.8% | -1.9% |
| 2018 | -0.6% | 0.3% |
| 2017 | 51.0% | 21.1% |
| 2016 | -28.0% | -20.6% |
| 2015 | -2.6% | -2.4% |
| 2014 | 29.9% | -0.9% |
| 2013 | 16.4% | -25.0% |
| 2012 | 16.3% | -8.3% |
| 2011 | 31.4% | 23.7% |
| 2010 | 5.5% | -7.4% |
| 2009 | 9.6% | -20.5% |
| 2008 | -28.3% | 11.9% |
| 2007 | 15.5% | 4.2% |
| 2006 | 0.7% | -8.1% |
| 2005 | 14.6% | -5.2% |
| 2004 | -11.2% | -14.9% |
| 2003 | 45.7% | 20.4% |
| 2002 | -44.1% | -29.4% |
| 2001 | -17.4% | -6.1% |
| 2000 | 14.1% | -32.8% |
| 1999 | 4.4% | 43.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Book Leverage Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Book Leverage signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.